Research Scientist / Lab Manager
Functional Genomics of Ankylosing Spondylitis
Giuseppe joined the Knight group (Genomics of Immunity, Wellcome Centre for Human Genetics) in 2015 as a researcher / project manager for the Arthritis UK (now Versus Arthritis) sponsored ankylosing spondylitis research project. Ankylosing spondylitis (AS) is highly heritable with over 40 disease-associated loci on recent genome-wide association studies (GWAS). In most cases, association involves regulatory DNA variants and the specific modulated gene(s), pathways and mechanism of action remain unresolved, limiting translational utility. The goal of this research is to determine the functional basis for genetic associations with AS to advance understanding of disease pathogenesis and define opportunities for therapeutic intervention.
Giuseppe graduated "110/110 con lode" (BSc 1st Hons equivalent) in Biological Sciences from “La Sapienza” University of Rome. He held several positions in the biotech industry, working in Quality Control, Research & Development and Customer Support Services at Amersham Biosciences (now GE Healthcare), contributing to the development of technologies and products used in genomics and proteomics research. In 2004 he joined a small research group at the Wellcome Trust Centre for Human Genetics, University of Oxford focusing on the development of a next generation sequencing scheme based on cyclic ligation. Between 2012 and 2015 he was part of the Screening and Assay Development group at the Structural Genomics Consortium, University of Oxford where he worked on screening inhibitors for human histone demethylases.
Comprehensive epigenomic profiling reveals the extent of disease-specific chromatin states and informs target discovery in ankylosing spondylitis
Brown AC. et al, (2023), Cell Genomics, 3, 100306 - 100306
Epigenomic analysis reveals a dynamic and context-specific macrophage enhancer landscape associated with innate immune activation and tolerance
Zhang P. et al, (2022), Genome Biology, 23
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity
Ahern DJ. et al, (2022), Cell, 185, 916 - 938.e58
A haemagglutination test for rapid detection of antibodies to SARS-CoV-2
Townsend A. et al, (2021), Nature Communications, 12
COMPREHENSIVE EPIGENOMIC PROFILING REVEALS DISEASE-SPECIFIC CHROMATIN STATES IN ANKYLOSING SPONDYLITIS
Cohen CJ. et al, (2021), CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 39, 1155 - 1155